| Demand visibility | Strong visibility in generic APIs and NCE services. |
|---|---|
| Management confidence | High confidence in regulatory compliance and global reach across 80+ countries. |
Growth
Portfolio expansion into specialized areas like Peptides (Difelikefalin) and complex APIs indicates higher value-add growth strategy.
Outlook
Strong pipeline in neurology, oncology, and antidiabetics with multiple products in the 'Commercial & Commercial-Scale' phase.
Risks
Dependence on patent expirations and successful regulatory filings (CEP/E-DMF) for commercial scale-up.
Earnings Call filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹21,890.00
- Market cap
- ₹28,085 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 56.4×Sector 50.4×
- Promoter holding
- 32.62%-0.01% QoQ
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Neuland Laboratories Capacity Expansion: ₹126 Cr Investment
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
- Value
- ₹126.0 Cr
- land acquisition
- 134.0 acres
Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
- Call
- Guides 20% growth
Neuland Laboratories Investor Presentation: Key Takeaways
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland Laboratories Q1 FY27 Results: Net Profit ₹147.7 Cr, Up 962.6% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹641.6 Cr (+119.1% YoY) and net profit of ₹147.7 Cr (+962.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹147.7 Cr · +962.6% YoY
Neuland Laboratories Earnings Call: Key Takeaways
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.